Among 258 patients with histologically confirmed epithelial cancers and EpCAM-positive tumor cells in ascitic fluid, those receiving catumaxomab plus paracentesis had a markedly prolonged median puncture-free survival (PuFS) compared to paracentesis alone [46 vs. 11 days; hazard ratio (HR) 0.2254; p < 0.0001]. Here, EPCAM is linked to neoplasm.